31438-75-2

Basic information

• Product Name: 3-METHOXY-4-(2-OXO-2-PIPERIDIN-1-YL-ETHOXY)-BENZALDEHYDE
• Synonyms: ZERENEX E/4047987;3-METHOXY-4-(2-OXO-2-PIPERIDIN-1-YL-ETHOXY)-BENZALDEHYDE
• CAS NO: 31438-75-2
• Molecular Formula: C15H19NO4
• Molecular Weight: 277.32
• Mol File: 31438-75-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-METHOXY-4-(2-OXO-2-PIPERIDIN-1-YL-ETHOXY)-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-4-(2-OXO-2-PIPERIDIN-1-YL-ETHOXY)-BENZALDEHYDE(31438-75-2)
• EPA Substance Registry System: 3-METHOXY-4-(2-OXO-2-PIPERIDIN-1-YL-ETHOXY)-BENZALDEHYDE(31438-75-2)

Safety Data

• Hazardous Substances Data: 31438-75-2(Hazardous Substances Data)

Usage

Chemical compound

3-Methoxy-4-(2-oxo-2-piperidin-1-yl-ethoxy)-benzaldehyde

Also known as

ML264
Selective inhibitor of phosphodiesterase 4B (PDE4B)
Studied for potential therapeutic applications in the treatment of inflammatory and neurodegenerative diseases
Considered a promising candidate for drug development
Ability to selectively target PDE4B, implicated in various pathological processes
Investigated for its potential to modulate cAMP signaling
Could have implications for the development of novel treatment strategies for a range of diseases

Upstream product

• 110-89-4 piperidine 
• 1440-60-4 1-chloroacetyl-piperidine 
• 121-33-5 vanillin 

Relevant articles and documents

Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents

A series of new (Z)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)benzylidene)indolin-2-one derivatives has been synthesized and evaluated for their cytotoxic activity against selected human cancer cell lines of prostate (PC-3 and DU-145), breast (BT-549 and MDA-MB-231) and non-tumorigenic prostate epithelial cells (RWPE-1). Among the tested, one of the compounds 4p exhibited potent cytotoxicity selectively on prostate cancer cell lines (PC-3 and DU-145; IC50: 1.89 ± 0.6 and 1.94 ± 0.2 μM, respectively). Further experiments were conducted with 4p on PC-3 cancer cells to study the mechanisms of growth inhibition and apoptosis inducing effect. Treatment of PC-3 cells with test compound 4p resulted in inhibition of cell migration through disorganization of F-actin protein. The flow-cytometry analysis results showed that the compound arrested PC-3 cancer cells in the G2/M phase of cell cycle in a dose dependent manner. Hoechst staining and annexin-V binding assay revealed that the compound 4p inhibited tumor cell proliferation through induction of apoptosis. Western blot studies demonstrated that the compound 4p treatment led to activation of caspase-3, increased expression of pro-apoptotic Bax and significantly decreased expression of anti-apoptotic Bcl-2 in human prostate cancer PC-3 cells. In addition, the mitochondrial membrane potential (ΔΦm) was also affected and the levels of intracellular Ca2+ were raised.